142 related articles for article (PubMed ID: 38608516)
1. SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.
Hadidchi R; Wang SH; Rezko D; Henry S; Coyle PK; Duong TQ
Mult Scler Relat Disord; 2024 Jun; 86():105613. PubMed ID: 38608516
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
3. New York Inner City Hospital COVID-19 Experience and Current Data: Retrospective Analysis at the Epicenter of the American Coronavirus Outbreak.
Mani VR; Kalabin A; Valdivieso SC; Murray-Ramcharan M; Donaldson B
J Med Internet Res; 2020 Sep; 22(9):e20548. PubMed ID: 32540837
[TBL] [Abstract][Full Text] [Related]
4. Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system.
Wei Q; Mease PJ; Chiorean M; Iles-Shih L; Matos WF; Baumgartner A; Molani S; Hwang YM; Belhu B; Ralevski A; Hadlock J
Lancet Digit Health; 2024 May; 6(5):e309-e322. PubMed ID: 38670740
[TBL] [Abstract][Full Text] [Related]
5. Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New York.
Kabarriti R; Brodin NP; Maron MI; Guha C; Kalnicki S; Garg MK; Racine AD
JAMA Netw Open; 2020 Sep; 3(9):e2019795. PubMed ID: 32975574
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.
Pinato DJ; Tabernero J; Bower M; Scotti L; Patel M; Colomba E; Dolly S; Loizidou A; Chester J; Mukherjee U; Zambelli A; Dalla Pria A; Aguilar-Company J; Ottaviani D; Chowdhury A; Merry E; Salazar R; Bertuzzi A; Brunet J; Lambertini M; Tagliamento M; Pous A; Sita-Lumsden A; Srikandarajah K; Colomba J; Pommeret F; Seguí E; Generali D; Grisanti S; Pedrazzoli P; Rizzo G; Libertini M; Moss C; Evans JS; Russell B; Harbeck N; Vincenzi B; Biello F; Bertulli R; Liñan R; Rossi S; Carmona-García MC; Tondini C; Fox L; Baggi A; Fotia V; Parisi A; Porzio G; Saponara M; Cruz CA; García-Illescas D; Felip E; Roqué Lloveras A; Sharkey R; Roldán E; Reyes R; Earnshaw I; Ferrante D; Marco-Hernández J; Ruiz-Camps I; Gaidano G; Patriarca A; Bruna R; Sureda A; Martinez-Vila C; Sanchez de Torre A; Cantini L; Filetti M; Rimassa L; Chiudinelli L; Franchi M; Krengli M; Santoro A; Prat A; Van Hemelrijck M; Diamantis N; Newsom-Davis T; Gennari A; Cortellini A;
Lancet Oncol; 2021 Dec; 22(12):1669-1680. PubMed ID: 34741822
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.
Eligulashvili A; Gordon M; Lee JS; Lee J; Mehrotra-Varma S; Mehrotra-Varma J; Hsu K; Hilliard I; Lee K; Li A; Essibayi MA; Yee J; Altschul DJ; Eskandar E; Mehler MF; Duong TQ
PLoS Med; 2024 Apr; 21(4):e1004263. PubMed ID: 38573873
[TBL] [Abstract][Full Text] [Related]
12. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in multiple sclerosis patients and risk factors for severe infection.
Chaudhry F; Bulka H; Rathnam AS; Said OM; Lin J; Lorigan H; Bernitsas E; Rube J; Korzeniewski SJ; Memon AB; Levy PD; Schultz L; Javed A; Lisak R; Cerghet M
J Neurol Sci; 2020 Nov; 418():117147. PubMed ID: 32980780
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
[TBL] [Abstract][Full Text] [Related]
15. Risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses: an electronic health record-based analysis from the RECOVER initiative.
L Mandel H; Colleen G; Abedian S; Ammar N; Charles Bailey L; Bennett TD; Daniel Brannock M; Brosnahan SB; Chen Y; Chute CG; Divers J; Evans MD; Haendel M; Hall MA; Hirabayashi K; Hornig M; Katz SD; Krieger AC; Loomba J; Lorman V; Mazzotti DR; McMurry J; Moffitt RA; Pajor NM; Pfaff E; Radwell J; Razzaghi H; Redline S; Seibert E; Sekar A; Sharma S; Thaweethai T; Weiner MG; Jae Yoo Y; Zhou A; Thorpe LE
Sleep; 2023 Sep; 46(9):. PubMed ID: 37166330
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study.
Barzegar M; Sindarreh S; Manteghinejad A; Mirmosayyeb O; Mazaheri S; Rahimi M; Javanmard SH; Shaygannejad V; Nasirian M
Mult Scler Relat Disord; 2023 Nov; 79():104947. PubMed ID: 37659351
[TBL] [Abstract][Full Text] [Related]
17. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection.
Ioannou GN; Locke E; Green P; Berry K; O'Hare AM; Shah JA; Crothers K; Eastment MC; Dominitz JA; Fan VS
JAMA Netw Open; 2020 Sep; 3(9):e2022310. PubMed ID: 32965502
[TBL] [Abstract][Full Text] [Related]
19. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
[TBL] [Abstract][Full Text] [Related]
20. Optic neuropathies post-Covid 19 - review.
Abdul-Salam State SE; Sfredel V; Mocanu CL; Albu CV; Bălășoiu AT
Rom J Ophthalmol; 2022; 66(4):289-298. PubMed ID: 36589322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
